Abstract
Introduction

Both primary hepatocellular carcinomas (HCC) and cancers metastasized to the liver are notoriously aggressive. Most patients with unresec tumours do not respond to existing systemic therapies
.
Recent advance include the approval of multikinase inhibitor sorafenib (Nexavar; Bayer, Morristown, NJ, USA) by the Food and Drug Administration for advanced HCC. Survival of these patients is improved for approximately 2 months [2]. Mortality of colorectal cancers (CRC) largely reflects the occurrence and progression of liver metastases, and treatment for metastatic CRC is nearly always
palliative [3] . Bevacizumab (Avastin; Genentech, San Francisco, CA, USA) is recently approved for metastatic CRC, and improved the survival by approximately 4 months when added to standard chemotherapy regimens [4] . These are important advancements for the treatment of these diseases. Some of these advanced primary and secondary liver cancers may also be addressed by locoregional therapies such as radiofrequency ablation and transarterial chemoembolization (TACE) or radioembolization, but only a minority of patients are eligible for these treatment options.
Therefore, novel therapies that act through mechanisms other than those of traditional therapies are urgently needed. In addition, patients will benefit from new therapies that not only prolong survival but also induce significantly higher response rates.
Viral oncolysis has been a recognized phenomenon in human beings for over a century, and engineered cancer-selective viruses have been tested for over a decade [5] . The safety of this therapeutic platform has been consistent, and antitumoural efficacy has been demonstrated in various tumour types [5, 6] . Pre-clinical [7] . This review summarizes laboratory and clinical studies in targeting these tumours with oncolytic viruses, and discusses unique challenges and opportunities for this field. [9] .
and clinical studies have identified HCC and other liver tumours as appropriate targets for oncolytic virotherapy. The underlying molecular pathology of these tumours renders them susceptible to hosting viral replication. These tumours are amenable to multiple routes of administration, including direct intratumoural (IT), intraarterial, intraportal, intrabiliary and intravenous (IV)
Pre-clinical studies
rVSV-GFP was also tested in a multifocal HCC animal model using hepatic arterial infusion (HAI) [10] . [14] .
JX-594 is a thymidine kinase-deleted, granulocyte macrophagecolony stimulating factor (GM-CSF)-expressing oncolytic poxvirus. IV delivery of JX-594 was well tolerated and showed efficacy against primary liver tumour, and successfully prevented lung metastases. JX-594 also showed efficacy in a carcinogen-induced
tumour model [15] . JX-594 has been tested in human melanoma patients, and safety and antitumoural efficacy has been demonstrated [16] . Based on these data, a phase I clinical trial testing JX-594 in patients with liver tumours was carried out [17, 18] .
Tumour [21] . IT administration of Onyx-015 for liver metastases was followed by studies using HAI [7, 22, 23] . Similar results were reported in pilot studies testing multiple administration routes [24, 25] [30] . [17, 18] Fig. 2A) . This is consistent with previous reports that the presence of circulating neutralizing antibodies does not preclude the antitumoural efficacy of locally delivered oncolytic virus [5, 7] . Phase II study with IT JX-594 in HCC is underway. [31] . While tumour sizes may remain unchanged, tumour necrosis may be induced by these agents, with objective clinical benefit [31] . These studies showed that new imaging criteria (e.g. Choi criteria) increases the prediction value of clinical benefit when compared to standard RECIST criteria [35] . For example, Choi criteria, currently applied to response assessment in gastrointestinal stromal tumours only, are being actively evaluated in several HCC trials with small molecules.
More recently, a clinical trial was conducted using oncolytic vaccinia virus JX-594 (TK-deleted/GM-CSF-expressing Wyeth strain vaccinia virus) in patients with liver tumours
Challenges for the use of virotherapy agents in liver tumour treatment
Fig. 1 (A) Systemic JX-594 genome levels after intratumoural administration. Reproduced from [17]. (B) Mathematical modelling of oncolytic virus
Onyx-015 replication after hepatic arterial infusion. Reproduced from [27] . [19] [6, 17, 27] (Fig. 1) . Systemic delivery, on (18) (Fig. 3) [18] . Possible mechanisms include induction of antiviral cytokines, many of which have been known to have anti-HBV effects (e.g. TNF-␣, IFN-␥) [18] . Whether this phenomenon is applicable to other HBV-or hepatitis C virus (HCV)-associated HCCs is yet to be determined. In addition, most patients with chronic HBV infection are also on chronic antiviral medications, and the impact of concurrent anti-hepatitis medications on oncolytic viruses needs to be studied. Testing virotherapeutics in HBV animal models [40] 
Similar phenomena have been noted for stereotactic radiotherapy, TACE, radioembolization, and ablative techniques such as radiofrequency ablation. Oncolytic virotherapy is another platform that will require modification of the paradigm of how to measure efficacy. Tumour necrosis is indeed a major mechanism of effective virotherapy. Therefore, response may be explained by changes in functional imaging such as fluorodeoxyglucosepositron emission tomgraphy (FDG-PET), and changes in vascularity as shown by perfusion computed tomography (CT)
